Logo

Atugen Signs RNAi Deal with Aventis

Sep 13, 2004

NEW YORK, Sept. 13 (GenomeWeb News) - Atugen said today that it has formed a collaboration with Aventis to identify siRNA compounds that have potential for development as therapeutics.

 

Atugen said the deal would combine its proprietary siRNA technology, including its stabilized siRNA compounds and delivery vehicles, with Aventis' pharmacology expertise "to inhibit pharmacologically relevant targets."

 

Additional terms of the deal were not disclosed.

 

Breaking News
The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.